The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Sudden Infant Death Syndrome

Sudden Infant Death Syndrome

Sudden Infant Death Syndrome (SIDS) is a tragic and perplexing condition characterized by the unexpected and unexplained death of an apparently healthy infant, typically occurring during sleep.
Researchers are continually striving to unravel the complex factors contributing to SIDS, in order to develop more effective prevention and treatment strategies.
PubCompare.ai's AI-driven platform offers a powerful tool to optimize this crucial research.
By leveraging advanced AI comparisons, the platform can help researchers locate the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
This unlocks new insights and drives breakthroughs in SIDS prevention and treatment, ultimately saving lives.

Most cited protocols related to «Sudden Infant Death Syndrome»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2018
Acquired Immunodeficiency Syndrome Aortic Aneurysm Caribbean People Disabled Persons Disorder, Attention Deficit-Hyperactivity Ethnicity Headache Disorders Low Back Pain Maternal Death Microtubule-Associated Proteins Neck Pain Population Group Sudden Infant Death Syndrome

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Acquired Immunodeficiency Syndrome Age Groups Aortic Aneurysm Disabled Persons Infant, Newborn Injuries Maternal Death Mothers MR 20 Noncommunicable Diseases Nutrition Disorders sequels Sudden Infant Death Syndrome
In GBD 2017, as in previous GBDs, causes of mortality and morbidity are structured using a four-level classification hierarchy to produce results that are mutually exclusive and collectively exhaustive. GBD 2017 estimates 359 causes of DALYs, 77 of which are a source of disability but not a cause of death (eg, attention-deficit hyperactivity disorder, headache disorders, low back pain, and neck pain), and five of which are causes of death but not sources of morbidity (sudden infant death syndrome, aortic aneurysm, late maternal deaths, indirect maternal deaths, and maternal deaths aggravated by HIV/AIDS). In the GBD hierarchy, the number of mutually exclusive and collectively exhaustive fatal and non-fatal causes in each level for which GBD estimates is three at Level 1, 22 at Level 2, 169 at Level 3, and 293 at Level 4. The full GBD cause hierarchy, including corresponding International Classification of Diseases (ICD)-9 and ICD-10 codes and detailed cause-specific methods, is in GBD 2017 publications on cause-specific mortality11 and non-fatal health outcomes12 in the corresponding appendices.
GBD 2017 includes 195 countries and territories that are grouped into 21 regions on the basis of epidemiological similarities and geographical proximity.15 (link) For the purposes of statistical analyses, we further grouped regions into seven super-regions (central Europe, eastern Europe, and central Asia; high income; Latin America and Caribbean; north Africa and Middle East; south Asia; southeast Asia, east Asia and Oceania; and sub-Saharan Africa). Each year, GBD includes subnational analyses for a few new countries and continues to provide subnational estimates for countries that were added in previous cycles. Subnational estimation in GBD 2017 includes five new countries (Ethiopia, Iran, New Zealand, Norway, and Russia) and countries previously estimated at subnational levels (GBD 2013: China, Mexico, and the UK [regional level]; GBD 2015: Brazil, India, Japan, Kenya, South Africa, Sweden, and the USA; and GBD 2016: Indonesia and the UK [local government authority level]). All analyses are at the first level of administrative organisation within each country except for New Zealand (by Māori ethnicity), Sweden (by Stockholm and non-Stockholm), and the UK (by local government authorites). All subnational estimates for these countries were incorporated into model development and evaluation as part of GBD 2017. To meet data use requirements, we present all subnational estimates excluding those pending publication (Brazil, India, Japan, Kenya, Mexico, Sweden, the UK, and the USA); these results are presented in appendix tables and figures (appendix 2). Subnational estimates for countries with populations larger than 200 million people (as measured according to our most recent year of published estimates) that have not yet been published elsewhere are presented wherever estimates are illustrated with maps but are not included in data tables.
Full text: Click here
Publication 2018
Acquired Immunodeficiency Syndrome Aortic Aneurysm Caribbean People Disabled Persons Disorder, Attention Deficit-Hyperactivity Ethnicity Headache Disorders Low Back Pain Maternal Death Microtubule-Associated Proteins Neck Pain Population Group Sudden Infant Death Syndrome

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Acquired Immunodeficiency Syndrome Aortic Aneurysm Disabled Persons Fatal Outcome Hookworm Infections Maternal Death Neck Pain Sudden Infant Death Syndrome Trachoma
The planned enrolment period for the Safe Passage Study is 7.5 years, from August 2007 to January 2015, with subsequent follow-up for 1 year post-delivery. The main study protocol is implemented for 12 000 pregnant women enrolled in the study, while an embedded study protocol includes a randomly selected subset of 3750 women who were enrolled prior to 24 weeks gestation and consented to additional study assessments. The incorporation of the embedded study provides more in-depth information pertinent to specific secondary hypotheses, while minimising costs and resources.
Power calculations utilised published rates of SIDS, stillbirth, and PAE (see Table 1 and Supporting Information Appendix S1) and information from a retrospective study of antecedent risk factors for SIDS in the NP American Indians [Aberdeen Area Infant Mortality Study (AAIMS)] reporting a relative risk (RR) of 6.7 for SIDS among women with PAE in the first trimester as compared to unexposed women.9 (link) Conservatively assuming that the risk of SIDS is tripled, 49% of women will be exposed to PAE during pregnancy, and 10% attrition, 11 622 women were required. The targeted sample size of 12 000 women enrolled (7000 from SA and 5000 in the NP) is expected to yield a sample of 98 stillbirths and 37 SIDS cases to ensure 80% power to detect an RR of 3 with a chi-square test for proportions with continuity correction and a two-sided level of significance of 5%. Based on the rates of stillbirth reported in Table 1 (8/1000 and 15/1000 in the NP and SA, respectively),14 ,15 (link) a sample size of 12 000 will ensure >95% power to detect an RR of at least 2 comparing women with PAE with those without PAE. The study is not designed to investigate genetic and biological interactions or perform subgroup analyses (e.g. by site, cause of death). However, these relationships will be explored as appropriate.
Publication 2014
American Indians Biopharmaceuticals Childbirth Obstetric Delivery Pregnancy Pregnant Women Sudden Infant Death Syndrome Tooth Attrition Woman

Most recents protocols related to «Sudden Infant Death Syndrome»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Congenital Abnormality Infection Premature Birth Sudden Infant Death Syndrome
This qualitative systematic literature review aimed at identifying the potential impact of short-term measures of the IMO’s Initial Strategy—more specifically slow steaming- on States, as reported in the literature. Particular attention was paid to the needs of developing countries, especially SIDS and LDCs, with regard to the eight impact criteria provided in MEPC.1/Circ.885 (MEPC 2019 ). This literature review process includes relevant peer-reviewed articles, and various relevant grey literature (non-peer reviewed) documents. A systematic process was used to collect peer reviewed literature, as well as grey literature, in order to provide an objective means of identifying the sources.
The literature was identified by keyword searches in the following abstract and citations databases: Scopus, Science Direct, Google Scholar, Research Gate, and EBSCO. The specific keywords and their combinations used were as follows: “slow steaming”, “speed reduction”, “impact assessment”, “engine power limit”, “shaft power limit”, “Developing Countries”, “SIDs”, “LDCs”, “connectivity”, “geographic remoteness”, “cargo value”, “cargo type”, “transport dependency”, “transport cost”, “freight”, “inventory cost”, “food security”, “disaster response”, “socio-economic progress and development”, “logistic” and “cargo quality”.
A total of 864 works in eight categories were initially identified. To select the most relevant articles, two criteria for inclusion and exclusion were considered (see Table 1). In the first filtering step, where titles, conclusions, abstracts and keywords were analysed and considered, 469 studies were excluded and only 395 articles that were found to be relevant according to exclusion criterion one (Table 1). In the second filtering step, the exclusion criterion two (Table 1) was applied after reading and analysing the whole text. In this second step, 315 articles were found not to explicitly contribute to the topic, and were then excluded. In addition, 15 articles were included through backward and forward snowballing, which resulted in a total of 95 documents. In a third filtering step, any works older than 2003 were excluded, leaving 62 articles in the final selection. With the help of figure one, the various filtering steps that served the methodology are summarised (Fig. 1).

Inclusion and exclusion criteria

Criterion one(Filtering step 1)Criterion two(Filtering step 2)Criterion three(Filtering step 3)
Peer reviewed articles and high quality conference papers, books, industrial and technical reports, which are relevant to research questions and address slow steaming within the eight impact criteria provided in MEPC.1/Circ.885Non-English studies, duplicate articles, non-peer reviewed articles, low quality industrial and technical reports, and articles that not totally covered the topicExclude texts older than 2003

The flow chart of the methodology

Full text: Click here
Publication 2023
2-methylphenyl cinnamate Attention Conferences Disasters Strains Sudden Infant Death Syndrome
The objective of this criminal search optimization algorithm (CSOA) [32 (link)] is to find the criminal by the evidence that is collected by the investigators. Cooperative jamming and power randomness are used to improve covertness performance [33 (link)]. To achieve the goal of CSOA, the entire process is segmented into four phases. These phases are explained below:
Phase 1: Initialization
This initialization process is carried out in this phase. Here the parameters, SI (sub-investigators), and the undercover officers are initialized that are being used by the CSOA. At first, all informants and SIs are obtaining suspects’ random information at their pre-defined search location. The parameters such as inqmax and Randommax represent maximum inquiries and the random numbers’ maximum limit, respectively.
Phase 2: Evaluating the Performance and Searching for the Criminal
The chief investigator (CI) collects all the information that is gathered by the informer and SI and creates the evidence against the accused person by using the objective function. Initially ( s=0 ), the defender is considered as primary suspect based on best fitness (evidence) as shown by below equation.
Ps=B[SIs*,Ins*]
The terms Ps is the primary suspects’ information that is available in CI; B represents the best, SIs* represents the accused persons’ best information available with the SI; and Ins* represents the accused persons’ best information available with the informers; then s is for investigation steps. In the following phases ( s0 ), the comparison is made between the primary accused persons’ present inquiry stage and previous inquiry stage to select the evidence of the present primary accused person by using Equation (4),
BInfos={priAPs        if e(priAPs)<e(priAPs1)priAPs1        else if e(priAPs)e(priAPs1)
In the above equation, the term BInfos represents the accused persons’ best information that is present with the CI; the term priAPs1  signifies the best prior information of the primary accused person with the CI; the terms e(priAPs) and e(priAPs1) represents the evidence after processing priAPs and priAPs1 information, respectively; in the beginning, viz. when s=0 , priAPs is considered as BInfos .
Phase 3: Update Information
The updating of information is carried out in three steps. They are:
Interrogation—The accused persons’ information with the investigator is upgraded using Equation (5).
BInfos+1=BInfos+BInfos×Rs
From the above equation, the term BInfos+1 represent the primary accused persons’ updated information; the term BInfos represents the primary accused persons’ present information which is available with CI; Rs is the random number with the range [−1, 1]. The term s is the investigation stages.
Information Updating of SI—The information from SI is upgraded by using Equation (6) in this step.
SIs+1=SIs+d1×SIBInfos+x×d2×SIys+(1x)×d3×SIds
The term SIs is the primary suspects’ present information that is available in SI; the term SIs+1 is the primary suspects’ updated information that is available in SI; the evidence gathered from the primary accused person by the SI is represented as SIBInfos and is given as ( BInfosSIs ). The evidence gathered from previous best evidence by SI is given as ( SIBInfos1SIs ) is represented by SIys . The evidence collected from random SI is given as ( SIdsSIs ) is represented by SIds . The random numbers from [0, dmax ] range are represented as d1,d2, and d3 and dmax is a random number with a maximum limit. Here x is an influencing factor with [0, 1] range random number which represents SI’s influence over evidence after comparing.
Information updating of Informer—The information from informer is upgraded by using Equation (7) in this step.
Is+1=Is+d1×Iys+d2×ISIs
The term Is define the accused persons’ evidence available with informers, the updated defender evidence present with the undercover officer is represented as Is+1 . Then the gathered evidence from previous evidence which is present with the undercover officer is shown as (Iys1Is) which is represented as Iys . The updated evidence gathered by an undercover officer from SI is represented as ISIs and it is given as ( SIs+1Is ).
Phase 4: Termination
After the information are updated from SI and informers, the updated data is reviewed to see if it is contained inside the search space. When the termination criteria ( s=smax ) is met, the inquiry is terminated and the primary accused person present is considered as criminal; otherwise, phases 2–4 are repeated.
Phase 5: Output
The final phase of CSOA is the output phase, here the culprit is announced. When the requirement of termination is reached the inquiry is terminated. The criminal informer is considered as suspect information that generates the strongest proof, and the accused person is declared as the criminal.
Full text: Click here
Publication 2023
Criminals Sudden Infant Death Syndrome
Modelling was conducted across five Pacific countries (Kiribati, Samoa, Solomon Islands, Tonga and Vanuatu) and four Caribbean countries (Barbados, Guyana, Jamaica and St Lucia), based on the availability of population surveys and data. They represent small, medium and large island types, with Jamaica representing nearly half of the total population of the English-speaking and Dutch-speaking Caribbean countries.
Annual demographic and epidemiological data that were used as model inputs are shown for each country in online supplemental materail tables A1–A4. Among these countries, most recent estimates of maternal mortality ratio ranged from 27 per 100 000 live births in Barbados to 169 per 100 000 live births in Guyana; unmet need for family planning ranged from 10.0% in Jamaica to 34.8% in Samoa; and fertility rates ranged from 1.4 in Saint Lucia to 4.4 in Solomon Islands (online supplemental material tables A3 and A4). In 2019, these countries were estimated to have GDP per capita ranging from US$1655 in Kiribati to US$23 267 in Barbados12 ; health spending ranging from 3.4% of GDP in Vanuatu to 10.2% of GDP in Kiribati (compared with 9.8% globally)13 and Universal Health Coverage Service Coverage Index ranging from 50 in Solomon Islands to 74 in Barbados and Guyana (compared with 67 globally).14
While there are differences among SIDS from the Caribbean and the Pacific, there are similarities between countries in their regional geography and relative isolation. They also share common challenges managing health-related workforce across multiple small islands, delivering education and obtaining commodities.15 16 (link)
Publication 2023
Caribbean People Head isolation Sudden Infant Death Syndrome

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Aged Caribbean People Diabetes Mellitus Human Development Sudden Infant Death Syndrome

Top products related to «Sudden Infant Death Syndrome»

Sourced in United States, United Kingdom, Germany
Cimetidine is a laboratory product manufactured by Merck Group. It is a chemical compound used in various research and analytical applications.
Sourced in United States, United Kingdom, Germany, China, Japan, Canada, France, Switzerland, Italy, Australia, Belgium, Spain, Denmark, Ireland, Netherlands, Holy See (Vatican City State), Israel
Opti-MEM is a cell culture medium designed to support the growth and maintenance of a variety of cell lines. It is a serum-reduced formulation that helps to reduce the amount of serum required for cell culture, while still providing the necessary nutrients and growth factors for cell proliferation.
Neurolucida is a cell counting program developed by MBF Biosciences. It provides users with tools to accurately count and analyze cells in microscopic images.
Sourced in United States, Germany
S-mephenytoin is a laboratory reagent used in the study of drug metabolism. It is a single enantiomer of the anticonvulsant drug mephenytoin. S-mephenytoin is primarily used as a probe substrate for the CYP2C19 enzyme, which is involved in the metabolism of certain drugs.
Sourced in United States, Japan, United Kingdom, Austria, Germany, Czechia, Belgium, Denmark, Canada
SPSS version 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data for research and business purposes. The software provides a range of statistical analysis tools and techniques, including regression analysis, hypothesis testing, and data visualization.
Sourced in United States, Germany, Sao Tome and Principe, China, United Kingdom, France, Czechia, Spain, India, Italy, Canada, Macao, Japan, Portugal, Brazil, Belgium
NADPH, or Nicotinamide Adenine Dinucleotide Phosphate, is a cofactor essential for various cellular processes. It plays a crucial role in enzymatic reactions, serving as an electron donor in oxidation-reduction reactions. NADPH is a key component in several metabolic pathways, including biosynthesis, antioxidant defense, and energy production.
Sourced in United States, Germany, United Kingdom, China, Canada, Japan, Italy, France, Netherlands, Switzerland, Denmark, Belgium, Australia
Lipofectamine is a cationic lipid-based transfection reagent used for the delivery of nucleic acids, such as plasmid DNA, small interfering RNA (siRNA), and messenger RNA (mRNA), into eukaryotic cells. It facilitates the formation of lipid-nucleic acid complexes that can be efficiently taken up by cells, enabling the introduction of genetic material into the cells for various research and experimental applications.
Sourced in United States, Germany, United Kingdom, France, Italy, Switzerland, Czechia, Sweden, Mexico
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is used as a pain reliever and anti-inflammatory agent. It is a commonly used pharmaceutical ingredient in various lab equipment and medical products.
Sourced in United States, Germany, China, Brazil, France, United Kingdom, Japan, Spain, Italy
Voriconazole is a laboratory product used as an antifungal agent. It is a synthetic triazole compound that inhibits the fungal enzyme lanosterol 14-alpha-demethylase, which is essential for the synthesis of ergosterol, a vital component of fungal cell membranes.
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, Czechia, China, Australia, Italy, Switzerland, Macao, France, Israel, Japan
Testosterone is a laboratory equipment product that measures the concentration of the hormone testosterone in biological samples. It is used in research and clinical settings to assess testosterone levels for various purposes, such as evaluating hormonal imbalances or monitoring treatment effects.

More about "Sudden Infant Death Syndrome"

Sudden Infant Death Syndrome (SIDS) is a devastating and puzzling condition characterized by the unexpected and unexplained death of an apparently healthy infant, typically occurring during sleep.
This tragic phenomenon has long puzzled researchers, who are continually striving to unravel the complex factors contributing to SIDS in order to develop more effective prevention and treatment strategies.
One powerful tool in this crucial research is PubCompare.ai's AI-driven platform, which offers a sophisticated approach to optimizing SIDS research.
By leveraging advanced AI comparisons, the platform can help researchers locate the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
This unlocks new insights and drives breakthroughs in SIDS prevention and treatment, ultimately saving lives.
Researchers investigating SIDS may also explore related topics and techniques, such as the use of Cimetidine, Opti-MEM, the Neurolucida cell counting program, S-mephenytoin, SPSS version 22.0, NADPH, Lipofectamine, Diclofenac, Voriconazole, and Testosterone.
These tools and compounds can provide valuable insights and inform the development of new strategies to combat this devastating condition.
By incorporating the latest research, cutting-edge technologies, and a multidisciplinary approach, the scientific community is making steady progress in unraveling the mysteries of Sudden Infant Death Syndrome.
With continued dedication and innovation, researchers are poised to deliver life-saving breakthroughs that will prevent countless tragedies and provide solace to grieving families.